ACADIA Pharmaceuticals Future Growth
Future criteria checks 5/6
ACADIA Pharmaceuticals is forecast to grow earnings and revenue by 61.6% and 23.7% per annum respectively while EPS is expected to grow by 60.6% per annum.
Key information
61.6%
Earnings growth rate
60.6%
EPS growth rate
| Biotechs earnings growth | 0% |
| Revenue growth rate | 23.7% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 10 Oct 2023 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 1,122 | 279 | 389 | 445 | 13 |
| 12/31/2024 | 885 | 112 | 181 | 212 | 17 |
| 12/31/2023 | 681 | -67 | -51 | -55 | 17 |
| 6/30/2023 | 551 | -111 | -74 | -34 | N/A |
| 3/31/2023 | 520 | -146 | -56 | -56 | N/A |
| 12/31/2022 | 517 | -216 | -114 | -114 | N/A |
| 9/30/2022 | 512 | -217 | -113 | -113 | N/A |
| 6/30/2022 | 512 | -205 | -130 | -130 | N/A |
| 3/31/2022 | 493 | -214 | -142 | -142 | N/A |
| 12/31/2021 | 484 | -168 | -127 | -126 | N/A |
| 9/30/2021 | 474 | -192 | -133 | -130 | N/A |
| 6/30/2021 | 463 | -262 | -141 | -136 | N/A |
| 3/31/2021 | 458 | -260 | -155 | -147 | N/A |
| 12/31/2020 | 442 | -282 | -144 | -136 | N/A |
| 9/30/2020 | 419 | -268 | -144 | -138 | N/A |
| 6/30/2020 | 393 | -225 | -139 | -134 | N/A |
| 3/31/2020 | 366 | -238 | -137 | -136 | N/A |
| 12/31/2019 | 339 | -235 | -152 | -151 | N/A |
| 9/30/2019 | 300 | -248 | -162 | -161 | N/A |
| 6/30/2019 | 264 | -268 | -186 | -184 | N/A |
| 3/31/2019 | 238 | -276 | -189 | -186 | N/A |
| 12/31/2018 | 224 | -245 | -170 | -167 | N/A |
| 9/30/2018 | 208 | -249 | -160 | -158 | N/A |
| 6/30/2018 | 185 | -252 | -175 | -174 | N/A |
| 3/31/2018 | 158 | -256 | -193 | -192 | N/A |
| 12/31/2017 | 125 | -289 | -219 | -218 | N/A |
| 9/30/2017 | 93 | -299 | -252 | -251 | N/A |
| 6/30/2017 | 63 | -306 | -243 | -242 | N/A |
| 3/31/2017 | 33 | -309 | N/A | -240 | N/A |
| 12/31/2016 | 17 | -271 | N/A | -208 | N/A |
| 9/30/2016 | 5 | -238 | N/A | -182 | N/A |
| 6/30/2016 | 0 | -206 | N/A | -165 | N/A |
| 3/31/2016 | 0 | -174 | N/A | -138 | N/A |
| 12/31/2015 | 0 | -164 | N/A | -122 | N/A |
| 9/30/2015 | 0 | -147 | N/A | -105 | N/A |
| 6/30/2015 | 0 | -133 | N/A | -91 | N/A |
| 3/31/2015 | 0 | -115 | N/A | -78 | N/A |
| 12/31/2014 | 0 | -92 | N/A | -66 | N/A |
| 9/30/2014 | 0 | -76 | N/A | -59 | N/A |
| 6/30/2014 | 0 | -62 | N/A | -51 | N/A |
| 3/31/2014 | 1 | -50 | N/A | -39 | N/A |
| 12/31/2013 | 1 | -38 | N/A | -32 | N/A |
| 9/30/2013 | 1 | -33 | N/A | -28 | N/A |
| 6/30/2013 | 5 | -24 | N/A | -24 | N/A |
| 3/31/2013 | 5 | -21 | N/A | -23 | N/A |
| 12/31/2012 | 5 | -21 | N/A | -22 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ACAD * is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (7.6%).
Earnings vs Market: ACAD * is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: ACAD * is expected to become profitable in the next 3 years.
Revenue vs Market: ACAD *'s revenue (23.7% per year) is forecast to grow faster than the MX market (6.2% per year).
High Growth Revenue: ACAD *'s revenue (23.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ACAD *'s Return on Equity is forecast to be high in 3 years time